Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH185425D
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for treatment of iron deficiency, a range of non prescription products for the treatment of infectious diseases, and iron based phosphate binder for controlling serum phosphorus levels in patients with chronic kidney disease undergoing dialysis. Vifor Pharma's clinical programs concentrates on safety and efficacy of Broncho Vaxom for respiratory tract infections in children and in chronic obstructive pulmonary disease in adults; and uro vaxom for recurrent urinary tract infections. It has manufacturing facilities in Switzerland, the UK and Portugal. Vifor Pharma is headquartered in Glattbrugg, Switzerland.

Vifor Pharma AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Relypsa Secures USD2.6 Million in Venture Funding 13

Relypsa Raises USUSD80 Million In Series C Financing 14

Relypsa Secures USD62.4 Million in Venture Funding 16

Partnerships 17

Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17

Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18

Probi Enters Into Co-Marketing Agreement With Vifor Pharma 19

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 20

Licensing Agreements 21

Zeria Pharma Enters into Licensing Agreement with Vifor Pharma 21

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 22

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 23

Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 24

Vifor Pharma Expands Licensing Agreement with Roche 26

Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 27

Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 28

Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 29

Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 30

Equity Offering 32

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 32

Relypsa Raises USD172 Million in Public Offering of Shares 33

Relypsa Completes Public Offering Of Shares For USUSD101.2 Million 35

Relypsa Completes IPO For USUSD86.7 Million 37

Acquisition 39

Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 39

Relypsa May Sell Itself 41

Vifor Pharma AG-Key Competitors 42

Vifor Pharma AG-Key Employees 43

Vifor Pharma AG-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 46

Financial Announcements 46

Mar 15, 2018: Vifor Pharma Group Reports Strong 2017 Results, Exceeding Raised Guidance 46

Aug 08, 2017: Vifor Pharma Reports Strong H1 2017 Results And Raises Guidance 51

Corporate Communications 52

Mar 29, 2018: Vifor Pharma to Propose Jacques Theurillat as Board Member 52

Government and Public Interest 53

Feb 20, 2017: Vifor Pharma and ECCO Announces One-Year Research Grant for Iron Deficiency 53

Clinical Trials 54

Feb 08, 2018: Vifor Pharma Ferroportin Inhibitor Enters Phase-I Clinical Trial 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Vifor Pharma AG, Pharmaceuticals & Healthcare, Key Facts 2

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vifor Pharma AG, Deals By Therapy Area, 2012 to YTD 2018 9

Vifor Pharma AG, Medical Devices Deals, 2012 to YTD 2018 10

Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Relypsa Secures USD2.6 Million in Venture Funding 13

Relypsa Raises USUSD80 Million In Series C Financing 14

Relypsa Secures USD62.4 Million in Venture Funding 16

Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 17

Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 18

Probi Enters Into Co-Marketing Agreement With Vifor Pharma 19

Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 20

Zeria Pharma Enters into Licensing Agreement with Vifor Pharma 21

Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 22

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 23

Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 24

Vifor Pharma Expands Licensing Agreement with Roche 26

Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 27

Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 28

Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 29

Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 30

Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 32

Relypsa Raises USD172 Million in Public Offering of Shares 33

Relypsa Completes Public Offering Of Shares For USUSD101.2 Million 35

Relypsa Completes IPO For USUSD86.7 Million 37

Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 39

Relypsa May Sell Itself 41

Vifor Pharma AG, Key Competitors 42

Vifor Pharma AG, Key Employees 43

Vifor Pharma AG, Other Locations 44

Vifor Pharma AG, Subsidiaries 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Vifor Pharma AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com